Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-debate-20260410-095546-8e85ab15",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Novel Hypotheses: α7β2 Heteromer Enrichment in Stellate Neurons\n\n---\n\n## Hypothesis 1: Subcellular Compartmentalization Hypothesis\n**Confidence: 0.72**\n\n**Description:** α7β2 heteromers may be preferentially localized to excitatory synaptic terminals (parallel fiber inputs) on stellate neurons rather than somatic regions. This compartmentalization would create functionally distinct calcium microdomains that modulate glutamate release probability and short-term plasticity. The β2 subunit's larger intracellular domain (compared to β4) may facilitate unique anchoring to PSD-95 family proteins, enabling this spatial specificity.\n\n**Target:** CHRNB2 (β2 nicotinic subunit), PSD-95/SAP97 scaffolding complex\n\n---\n\n## Hypothesis 2: Developmental Switch Hypothesis\n**Confidence: 0.65**\n\n**Description:** Stellate neuron circuits exhibit an α7→α7β2 developmental transition during adolescence that functionally reshapes signal integration. Broad α7 targeting in trials may have inadvertently disrupted developmental plasticity processes in young subjects while providing insufficient modulation in adults where α7β2 predominates. This would explain both trial failures (wrong population/dosing window) and support selectivity-based strategies.\n\n**Target:** CHRNA7/CHRNB2 developmental expression regulators (Mash1, Ngn2 transcription factors)\n\n---\n\n## Hypothesis 3: Astrocyte-Neuron Metabolic Coupling Hypothesis\n**Confidence: 0.58**\n\n**Description:** Stellate neurons expressing α7β2 may form specialized metabolic coupling units with nearby astrocytes via α7-mediated calcium signaling. Activation triggers astrocytic lactate release, which feeds the high metabolic demand of stellate neurons during high-frequency firing. Failed clinical trials using broad α7 agonists may have disrupted this coupling by non-physiological receptor activation patterns, causing metabolic dysregulation rather than benefit.\n\n**Target:** CHRNA7/CHRNB2 heteromer, GLUT1/GLUT3 glucose transporters, MCT4 astrocytic lactate transporters\n\n---\n\n## Hypothesis 4: Cholinergic Input-Specific Filtering Hypothesis\n**Confidence: 0.70**\n\n**Description:** α7β2 heteromers in stellate neurons may uniquely filter specific cholinergic afferents (e.g., from medial septum/diagonal band) based on temporal dynamics. The β2 subunit slows desensitization kinetics compared to homomeric α7, allowing integration of phasic cholinergic signals over longer windows. This creates a temporal filtering mechanism that broad α7 agonists cannot replicate, explaining therapeutic failure from non-physiological activation patterns.\n\n**Target:** CHRNA7-CHRNB2 interface (intracellular domain), CHAT-positive cholinergic terminals\n\n---\n\n## Hypothesis 5: Nicotinic-Muscarinic Crosstalk Hypothesis\n**Confidence: 0.63**\n\n**Description:** α7β2 heteromers may physically associate with M1 muscarinic receptors in stellate neuron dendrites, creating unique α7β2-M1 signaling complexes with distinct pharmacology. Failed broad α7 trials may have inadvertently disrupted these crosstalk mechanisms by driving desensitization of the heteromer while leaving M1 signaling unopposed, causing net inhibitory effects onstellate output. Selective α7β2 modulators could preserve M1 crosstalk while enhancing nicotinic signaling.\n\n**Target:** CHRNA7-CHRNB2 complex, CHRM1 (M1 muscarinic receptor), Homer1b/c scaffolding\n\n---\n\n## Hypothesis 6: Lynx-Based Endogenous Modulation Hypothesis\n**Confidence: 0.55**\n\n**Description:** Endogenous modulatory proteins (Lynx1, Lynx2) differentially regulate α7β2 vs. homomeric α7 due to distinct subunit interfaces. Stellate neurons express high Lynx2, creating an \"inhibited reserve\" of α7β2 receptors available only during intense cholinergic signaling. Clinical trials failed because systemically administered α7 agonists lacked the specificity to engage this Lynx-constrained pool; selective α7β2 positive allosteric modulators (PAMs) would preferentially access this functionally relevant pool.\n\n**Target:** LYNX1/LYNX2 endogenous modulatory proteins, α7β2 orthosteric site configuration\n\n---\n\n## Hypothesis 7: Electrophysiological Fingerprint Hypothesis\n**Confidence: 0.78**\n\n**Description:** α7β2 heteromers produce distinguishable current signatures in stellate neurons: faster deactivation kinetics, reduced calcium permeability, and altered single-channel conductance compared to homomeric α7. This creates an electrophysiological \"fingerprint\" that could be used to confirm enrichment pharmacologically. The β2 subunit creates a functional phenotype amenable to selective pharmacological dissection, providing both mechanistic insight and a biomarker for identifying stellate neurons in intact circuits.\n\n**Target:** CHRNA7-CHRNB2 heteromer functional properties, single-channel conductance differences\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Confidence | Key Target |\n|---|------------|------------|------------|\n| 1 | Subcellular compartmentalization | 0.72 | PSD-95 family |\n| 2 | Developmental switch | 0.65 | Transcription factors |\n| 3 | Astrocyte-metabolic coupling | 0.58 | MCT4, GLUT transporters |\n| 4 | Cholinergic input filtering | 0.70 | α7β2 interface |\n| 5 | Nicotinic-muscarinic crosstalk | 0.63 | M1 muscarinic receptor |\n| 6 | Lynx-based modulation | 0.55 | Lynx1/2 proteins |\n| 7 | Electrophysiological fingerprint | 0.78 | CHRNA7-CHRNB2 |\n\n**Highest Priority for Validation:** Hypothesis 7 provides the most tractable experimental approach using patch-clamp pharmacology to directly test α7β2 presence in stellate neurons before proceeding to mechanistic hypotheses.",
  "tokens_used": "1394"
}